Cannabigerol Purification Without Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cannabigerol suffer from low purity and efficiency due to polyalkylation and regioisomer formation during Friedel-Crafts-Alkylation, necessitating costly and time-consuming chromatographic purifications.
Innovation Solution
A method involving the reaction of olivetol with allylic compounds having a leaving group in the presence of an acidic or Lewis acidic catalyst, followed by distillation and liquid-liquid extraction, to selectively separate cannabigerol from regioisomers and other impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Friedel-Crafts-Alkylation is used to synthesize cannabigerol, then the reaction can proceed, but polyalkylation and regioisomer formation occur leading to low purity
Solution Approach 1:
The patent converts the harmful polyalkylation side reaction into a beneficial selective purification mechanism. By allowing polyalkylation to occur with excess allylic compound, the unwanted polyalkylated regioisomers are formed in high concentration, which then enables their selective removal through crystallization of the desired cannabigerol product, achieving high purity without complex chromatography
Solution Approach 2:
The patent changes the reaction parameters by using excess allylic compound (1.5-3 equivalents) and controlling temperature (0-50°C), which shifts the reaction outcome from a mixture of products to a regime where the desired monoalkylation product can be selectively isolated through subsequent crystallization, improving both yield and purity
2Manufacturing precision
If chromatographic purification is used to separate cannabigerol from impurities, then high purity can be achieved, but the process becomes costly and time-consuming
Solution Approach 1:
The patent replaces the mechanical/chromatographic purification system with a simple crystallization process. By controlling the reaction conditions and using excess allylic compound, the desired cannabigerol crystallizes selectively from the reaction mixture, eliminating the need for time-consuming and expensive chromatographic columns and resins
Solution Approach 2:
The patent eliminates the need for expensive, complex chromatographic equipment by using a simple, inexpensive crystallization process that can be performed in standard laboratory glassware. The purification is achieved through a disposable crystallization step rather than requiring costly chromatographic materials
3Productivity
If excess allylic compound is used to drive the reaction, then yield improves, but polyalkylation side products increase
Solution Approach 1:
The patent converts the harmful effect of excess allylic compound causing polyalkylation into a beneficial purification mechanism. The polyalkylated regioisomers formed in excess are selectively removed through crystallization, allowing the use of excess reagent to drive the main reaction forward while the side products are easily separated, improving overall yield and purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves cannabigerol purity of 40-80% for subsequent crystallization, resulting in a final purity of >99% without the need for chromatographic methods, thereby improving yield and reducing costs.
Implementation Method 1
reacting olivetol with one or a mixture of two or more allylic compound(s) having a leaving group in the presence of an acidic or lewis acidic catalyst
Implementation Method 2
purifying the product by distillation or liquid-liquid extraction
Implementation Method 3
purifying the product by distillation or liquid-liquid extraction
Data Source
AI summary
The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and/or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and/or prevention of malign skin disorders, in particular skin cancer.


